» Articles » PMID: 38690024

Mechanisms of Tumor Immunosuppressive Microenvironment Formation in Esophageal Cancer

Overview
Specialty Gastroenterology
Date 2024 May 1
PMID 38690024
Authors
Affiliations
Soon will be listed here.
Abstract

As a highly invasive malignancy, esophageal cancer (EC) is a global health issue, and was the eighth most prevalent cancer and the sixth leading cause of cancer-related death worldwide in 2020. Due to its highly immunogenic nature, emer-ging immunotherapy approaches, such as immune checkpoint blockade, have demonstrated promising efficacy in treating EC; however, certain limitations and challenges still exist. In addition, tumors may exhibit primary or acquired resistance to immunotherapy in the tumor immune microenvironment (TIME); thus, understanding the TIME is urgent and crucial, especially given the im-portance of an immunosuppressive microenvironment in tumor progression. The aim of this review was to better elucidate the mechanisms of the suppressive TIME, including cell infiltration, immune cell subsets, cytokines and signaling pathways in the tumor microenvironment of EC patients, as well as the downregulated expression of major histocompatibility complex molecules in tumor cells, to obtain a better understanding of the differences in EC patient responses to immunotherapeutic strategies and accurately predict the efficacy of immunotherapies. Therefore, personalized treatments could be developed to maximize the advantages of immunotherapy.

Citing Articles

Leveraging Single-Cell Multi-Omics to Decode Tumor Microenvironment Diversity and Therapeutic Resistance.

Sabit H, Arneth B, Pawlik T, Abdel-Ghany S, Ghazy A, Abdelazeem R Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861138 PMC: 11768313. DOI: 10.3390/ph18010075.


Tumor-Infiltrating Lymphocytes in Resected Esophageal and Gastric Adenocarcinomas Do Not Correlate with Tumor Regression Score After Neoadjuvant Chemotherapy: Results of a Case-Series Study.

Seretis F, Glava C, Smparounis S, Riga D, Karantzikos G, Theochari M Cancers (Basel). 2024; 16(21).

PMID: 39518132 PMC: 11545232. DOI: 10.3390/cancers16213694.


Aryl hydrocarbon receptor dynamics in esophageal squamous cell carcinoma: From immune modulation to therapeutic opportunities.

Rahmati M, Moghtaderi H, Mohammadi S, Al-Harrasi A World J Exp Med. 2024; 14(3):96269.

PMID: 39312702 PMC: 11372732. DOI: 10.5493/wjem.v14.i3.96269.

References
1.
King R, Qiu F, Yu F, Singh P . Metabolic and Immunological Subtypes of Esophageal Cancer Reveal Potential Therapeutic Opportunities. Front Cell Dev Biol. 2021; 9:667852. PMC: 8295652. DOI: 10.3389/fcell.2021.667852. View

2.
Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N . The cancer metabolic reprogramming and immune response. Mol Cancer. 2021; 20(1):28. PMC: 7863491. DOI: 10.1186/s12943-021-01316-8. View

3.
Wang L, Han H, Wang Z, Shi L, Yang M, Qin Y . Targeting the Microenvironment in Esophageal Cancer. Front Cell Dev Biol. 2021; 9:684966. PMC: 8427432. DOI: 10.3389/fcell.2021.684966. View

4.
Zheng Y, Li Y, Tang B, Zhao Q, Wang D, Liu Y . IL-6-induced CD39 expression on tumor-infiltrating NK cells predicts poor prognosis in esophageal squamous cell carcinoma. Cancer Immunol Immunother. 2020; 69(11):2371-2380. PMC: 11027717. DOI: 10.1007/s00262-020-02629-1. View

5.
Lu B, Chen L, Liu L, Zhu Y, Wu C, Jiang J . T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract. Immunol Res. 2011; 50(2-3):269-75. DOI: 10.1007/s12026-011-8227-9. View